Loading company…
StemSight develops stem cell-based therapies and bioprinted corneal tissue for people with corneal blindness.
Founded in 2021 and based in Tampere, Finland, StemSight develops off-the-shelf cell therapies for corneal blindness using induced pluripotent stem cells and functional biomaterials. Its work includes bioprinting full-thickness corneas through the EU-funded KeratOPrinter project. In February 2025, the company raised EUR 2.3 million, with Voima Ventures leading the round and Stephen Industries, Biothom, and Business Finland Venture Capital participating.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in